Feinstein James A, Feudtner Chris, Valuck Robert J, Kempe Allison
Adult and Child Center for Health Outcomes Research and Delivery Science, Children's Hospital Colorado, University of Colorado, Aurora, CO, USA.
Division of General Pediatrics, University of Colorado, Aurora, CO, USA.
Pharmacoepidemiol Drug Saf. 2015 Oct;24(10):1049-57. doi: 10.1002/pds.3843. Epub 2015 Aug 7.
Outpatient pediatric polypharmacy is poorly characterized. Identification of at-risk populations has clinical implications for pharmacy case management programs. We described the degree of exposure to polypharmacy using parameters of depth (concurrent medication count) and duration, reported commonly dispensed medications and exposure to three example potential drug-drug interactions by different depths of polypharmacy, and determined patient characteristics associated with exposure to increased degrees (a function of depth and duration) of polypharmacy.
Retrospective cohort study of Colorado fee-for-service Medicaid patients aged <18 years with 12 months of continuous enrollment. We calculated depth of polypharmacy using daily concurrent medication counts and duration of polypharmacy using days exposed to a certain depth. Multinomial logistic regression was used to assess patient characteristics associated with different degrees of polypharmacy.
Of 242 230 patients, 35% percent were exposed to any depth of polypharmacy, most commonly to anti-infective medications. Patients with higher depth polypharmacy were exposed to less common medications (psychotropic drugs, anticonvulsants, cardiovascular agents, and opioids) and to higher rates of exposure to potential drug-drug interactions. Of 47 972 patients exposed to ≥3 concurrent medications, 50% were exposed for <15 days, 25% for 15-38 days, 15% for 39-111 days, and 10% for 112-327 days. High-degree polypharmacy was associated with increasing age, male gender, and presence of a complex chronic condition.
Outpatient pediatric polypharmacy occurs to a substantial degree for a small but vulnerable population of children, who may be candidates for pharmacy case management. We must determine whether increased exposure to high-degree polypharmacy causes harm.
门诊儿科多重用药情况的特征尚不明确。识别高危人群对药学病例管理项目具有临床意义。我们使用深度(同时服用药物数量)和持续时间参数描述了多重用药的暴露程度,报告了常用的配药药物以及不同深度多重用药情况下三种示例潜在药物相互作用的暴露情况,并确定了与更高程度(深度和持续时间的函数)多重用药暴露相关的患者特征。
对科罗拉多州按服务收费的医疗补助计划中年龄小于18岁且连续参保12个月的患者进行回顾性队列研究。我们使用每日同时服用药物数量计算多重用药的深度,并使用暴露于特定深度的天数计算多重用药的持续时间。采用多项逻辑回归评估与不同程度多重用药相关的患者特征。
在242230名患者中,35%的患者暴露于任何深度的多重用药,最常见的是抗感染药物。深度较高的多重用药患者接触的是不太常见的药物(精神药物、抗惊厥药、心血管药物和阿片类药物),且潜在药物相互作用的暴露率更高。在47972名同时服用≥3种药物的患者中,50%的患者暴露时间小于15天,25%的患者暴露时间为15 - 38天,15%的患者暴露时间为39 - 111天,10%的患者暴露时间为112 - 327天。高度多重用药与年龄增长、男性性别以及复杂慢性病的存在有关。
门诊儿科多重用药在一小部分但易受影响的儿童人群中相当普遍,这些儿童可能是药学病例管理的对象。我们必须确定更高程度的多重用药暴露是否会造成伤害。